To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
NCT ID: NCT04500132
Last Updated: 2022-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
63 participants
INTERVENTIONAL
2020-05-28
2021-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia
NCT04542044
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia
NCT04372186
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
NCT04409262
Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT04581135
A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
NCT00042588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EC-18 Arm
EC-18 QD
EC-18
EC-18 QD
Placebo Arm
Placebo EC-18 QD
Placebo EC-18
Placebo EC-18 QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EC-18
EC-18 QD
Placebo EC-18
Placebo EC-18 QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female age 19 years or older
* Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia
Exclusion Criteria
* Pregnant or nursing at the time of signing informed consent
* Known sensitivity to any study medication
* Unwilling or unable to complete study diary
* Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Enzychem Lifesciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyewon Jeong
Role: PRINCIPAL_INVESTIGATOR
Chungbuk National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungbuk National University Hospital
Cheongju-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC-18-C201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.